249 related articles for article (PubMed ID: 36611046)
1. Increased expression of TBC1D10B as a potential prognostic and immunotherapy relevant biomarker in liver hepatocellular carcinoma.
Fan L; Tang Y; Li J; Huang W
Sci Rep; 2023 Jan; 13(1):335. PubMed ID: 36611046
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
4. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.
Liu T; Li ZZ; Sun L; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Cancer; 2023 Oct; 23(1):1007. PubMed ID: 37858061
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
6. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
7. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
8. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.
Huang S; Hou Y; Hu M; Hu J; Liu X
BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627
[TBL] [Abstract][Full Text] [Related]
10. MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma.
Huang J; Chen X; Zhu W
Medicine (Baltimore); 2021 Mar; 100(12):e25234. PubMed ID: 33761715
[TBL] [Abstract][Full Text] [Related]
11. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
13. Analysis of TRIM27 prognosis value and immune infiltrates in hepatocellular carcinoma.
Wang H; Zhang Y; Yan L; Lv Q; Lu J; Yun B
Int J Immunopathol Pharmacol; 2022; 36():3946320221132986. PubMed ID: 36217828
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of aberrantly expressed methylation‑driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas.
Li J; Chen N; Gong X
Mol Med Rep; 2019 Dec; 20(6):5304-5314. PubMed ID: 31661127
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
16. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis.
Cui Y; Zhou Z; Chai Y; Zhang Y
J Immunol Res; 2021; 2021():7753553. PubMed ID: 34957313
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining.
Le Y; Kong H; Gao X; Zhu J
Comput Math Methods Med; 2022; 2022():8371885. PubMed ID: 36017155
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Tang H; You T; Sun Z; Bai C
BMC Cancer; 2022 Feb; 22(1):197. PubMed ID: 35189839
[TBL] [Abstract][Full Text] [Related]
19. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
20. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
